Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1111/bjh.19148
Keywords
BCMA; bispecific antibody; CAR-T; CAR T-Cells; GPRC5D; multiple myeloma
Categories
Ask authors/readers for more resources
This retrospective single-centre study investigated the outcomes of relapsed multiple myeloma patients who failed various treatments, and found that patients who failed anti-BCMA therapy had poor prognosis, highlighting the unmet medical need in this population.
Very scarce data exist about outcomes of relapsed multiple myeloma patients who have failed proteasome inhibitor, immunomodulatory drug, anti-CD38 monoclonal antibody and therapies targeting B-cell maturation antigen (BCMA) (Quad-class exposed [QCE]). In this retrospective single-centre study, we determined progression-free survival (PFS) and overall survival (OS) from anti-BCMA failure in 45 QCE patients. Seven (16%) patients received antibody-drug conjugate, 20 (44%) bispecific antibodies and 18 (40%) CAR-T cell. Thirty patients (67%) received >= 1 subsequent line of treatment. PFS was 4.4 months (95% CI = 2.4-12.5) and OS 6.3 months (95% CI = 3.9-14.4). Having an adverse prognosis, QCE myeloma patients remain an unmet medical need.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available